DRINK THE NEKTAR NEKTAR NKTR â H2 Filled With Events Across Deep Pipeline, Focus â181 Data And Then Some â Nektar is expected to deliver progress in the second half of 2013 in various proprietary and partnered programs, highlighting the depth and breadth of its platform technologies. In Q3, partner AstraZeneca is expected to file[…]
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.